(NASDAQ: MNKD) Mannkind's forecast annual revenue growth rate of 14.91% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.64%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.77%.
Mannkind's revenue in 2026 is $360,783,000.On average, 10 Wall Street analysts forecast MNKD's revenue for 2026 to be $145,734,882,804, with the lowest MNKD revenue forecast at $133,985,507,991, and the highest MNKD revenue forecast at $159,603,655,756. On average, 10 Wall Street analysts forecast MNKD's revenue for 2027 to be $164,630,274,956, with the lowest MNKD revenue forecast at $138,372,600,348, and the highest MNKD revenue forecast at $185,231,072,025.
In 2028, MNKD is forecast to generate $169,140,947,380 in revenue, with the lowest revenue forecast at $135,338,709,718 and the highest revenue forecast at $196,359,457,005.